Sun Pharmaceutical Industries informs about press release

21 Jul 2025 Evaluate

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release by Sun Pharmaceutical Industries (together with its subsidiaries / affiliated companies, ‘Sun Pharma’) about ‘Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint’.

The above information is a part of company’s filings submitted to BSE. 

Sun Pharma Inds. Share Price

1669.20 -31.35 (-1.84%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×